surmount-1 tirzepatide non-diabetic obesity weight loss after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial surmount-1 trial tirzepatide obesity without

In adults with obesity, tirzepatide produced substantial average weight reduction over 72 weeks, but individual outcomes varied considerably

Alternative diabetes treatments include injectable GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors, or traditional oral agents if heartburn persists despite management strategies

Phentermine is a sympathomimetic amine (stimulant) that suppresses appetite by increasing norepinephrine activity

The practical difference: each additional receptor target has produced better weight loss results in trials

Implications in cardiac muscle gene regulation during hypertrophy

This article focuses on the injectable research version of Retatrutide and the supporting evidence behind each lesser-known benefit